Skip to main content
Clinical Trials/EUCTR2019-002002-43-ES
EUCTR2019-002002-43-ES
Active, Not Recruiting
Phase 1

Phase IV, unicentric, randomized and open study to confirm the decrease of the incidence of the surgical site infection after elective right hemicolectomy with anterographic mechanical preparation associated with oral and intravenous antibiotic therapy versus oral and intravenous antibiotic and versus only intravenous antibiotic

Fundación Instituto de Investigación Sanitaria Aragón0 sites108 target enrollmentOctober 21, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients undergoing right hemicolectomy
Sponsor
Fundación Instituto de Investigación Sanitaria Aragón
Enrollment
108
Status
Active, Not Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 21, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients older than 18 years with surgical indication of right hemicolectomy who do not present any exclusion criteria.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 90
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 18

Exclusion Criteria

  • 1\. Patients under 18 years.
  • 2\. Urgent colorectal resections.
  • 3\. Patients presenting an occlusive or sub\-occlusive condition at the time of surgery.
  • 4\. Patient who does not meet the inclusion criteria in the intensified recovery program based on the RICA route (Intensified Recovery in Abdominal Surgery)
  • 5\. Patients undergoing colonic resection that involve a location other than the right colon.
  • 6\. Patients affected by intra\-abdominal or distant infection prior to surgery.
  • 7\. Patients who have been given antibiotics for any other indication during the two weeks prior to the intervention.
  • 8\. Patient with inflammatory bowel disease.
  • 9\. Pregnant or breastfeeding patient.
  • 10\. Patients with immunity disorders or receiving immunosuppressive treatment or with synchronous neoplasms of other organs at the time of surgery.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
N/A
A phase IV, open, randomized, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine and Baxter’s Neisseria meningitidis C conjugate vaccine versus separate administration of each of the vaccines in healthy children aged 12 through 23 months. - MMRV-060Active immunization of healthy children during their second year of life against measles, mumps, rubella, varicella and Neisseria meningitidis C diseases
EUCTR2008-003318-81-DEGlaxoSmithKline Biologicals708
Active, Not Recruiting
Phase 1
This study compares clinically and microscopically the response to two treatments, a steroid in cream and a foam that contains a steroid and a vitamin D analogue in patients with plaque psoriasis.Plaque psoriasisTherapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2017-004451-24-ESFundació Clínic per a la Reserca Biomèdica36
Active, Not Recruiting
Phase 1
A study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in HIV+ patients.
EUCTR2019-000199-41-ESFundación SEIMC-GESIDA234
Active, Not Recruiting
Phase 1
Study to evaluate the impact of early treatment with a budesonide / formoterol versus standard of care on the evolution of the disease in vulnerable patients with COVID-19: INHALAVID TrialEnfermedad en pacientes vulnerables con COVID-19MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2020-005280-31-ESFundació Eurecat200
Active, Not Recruiting
Phase 4
Comparison of combination of Diclofenac, Paracetamol, Trypsin, and Chymotrypsin versus combination of Diclofenac and Paracetamol in patient with soft tissue enjury.Health Condition 1: M799- Soft tissue disorder, unspecified
CTRI/2021/01/030508Cachet Pharmaceutical Pvt Ltd220